MedTrace Logo

Study to Investigate the Pharmacokinetics, Safety, and Tolerability of BMT101 in Healthy Male Volunteers

NCT03133130 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2018-04-25

No results posted yet for this study

Summary

Phase I Study to Investigate the Pharmacokinetics, Safety, and Tolerability of BMT101 in Healthy Male Volunteers

Conditions

  • Hypertrophic Scar

Interventions

DRUG

BMT101

BMT101 is administered to 6 subjects in each of 4 groups.

DRUG

Placebo

Placebo is administered to 2 subjects in each of 4 groups.

Sponsors & Collaborators

  • Hugel

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
39 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-07-31
Primary Completion
2018-02-14
Completion
2018-02-14

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03133130 on ClinicalTrials.gov